391 related articles for article (PubMed ID: 32222129)
21. Everolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.
Franz DN
Biologics; 2013; 7():211-21. PubMed ID: 24143074
[TBL] [Abstract][Full Text] [Related]
22. Proteomic analysis of murine Tsc1-deficient neural stem progenitor cells.
Chiaradia E; Miller I; Renzone G; Tognoloni A; Polchi A; De Marco F; Tancini B; Scaloni A; Magini A
J Proteomics; 2023 Jul; 283-284():104928. PubMed ID: 37207814
[TBL] [Abstract][Full Text] [Related]
23. Tuberous sclerosis complex-associated angiomyolipomas: focus on mTOR inhibition.
Budde K; Gaedeke J
Am J Kidney Dis; 2012 Feb; 59(2):276-83. PubMed ID: 22130643
[TBL] [Abstract][Full Text] [Related]
24. Everolimus as adjunctive therapy for tuberous sclerosis complex-associated partial-onset seizures.
Lechuga L; Franz DN
Expert Rev Neurother; 2019 Oct; 19(10):913-925. PubMed ID: 31335226
[No Abstract] [Full Text] [Related]
25. Mammalian Target of Rapamycin Inhibitors and Life-Threatening Conditions in Tuberous Sclerosis Complex.
Moavero R; Romagnoli G; Graziola F; Curatolo P
Semin Pediatr Neurol; 2015 Dec; 22(4):282-94. PubMed ID: 26706015
[TBL] [Abstract][Full Text] [Related]
26. The association of neurodevelopmental abnormalities, congenital heart and renal defects in a tuberous sclerosis complex patient cohort.
Robinson J; Uzun O; Loh NR; Harris IR; Woolley TE; Harwood AJ; Gardner JF; Syed YA
BMC Med; 2022 Apr; 20(1):123. PubMed ID: 35440050
[TBL] [Abstract][Full Text] [Related]
27. Neurological and neuropsychiatric aspects of tuberous sclerosis complex.
Curatolo P; Moavero R; de Vries PJ
Lancet Neurol; 2015 Jul; 14(7):733-45. PubMed ID: 26067126
[TBL] [Abstract][Full Text] [Related]
28. TuberOus SClerosis registry to increase disease Awareness (TOSCA) - baseline data on 2093 patients.
Kingswood JC; d'Augères GB; Belousova E; Ferreira JC; Carter T; Castellana R; Cottin V; Curatolo P; Dahlin M; de Vries PJ; Feucht M; Fladrowski C; Gislimberti G; Hertzberg C; Jozwiak S; Lawson JA; Macaya A; Nabbout R; O'Callaghan F; Benedik MP; Qin J; Marques R; Sander V; Sauter M; Takahashi Y; Touraine R; Youroukos S; Zonnenberg B; Jansen AC;
Orphanet J Rare Dis; 2017 Jan; 12(1):2. PubMed ID: 28057044
[TBL] [Abstract][Full Text] [Related]
29. The role of TSC1 and TSC2 proteins in neuronal axons.
Karalis V; Wood D; Teaney NA; Sahin M
Mol Psychiatry; 2024 Apr; 29(4):1165-1178. PubMed ID: 38212374
[TBL] [Abstract][Full Text] [Related]
30. Everolimus: an mTOR inhibitor for the treatment of tuberous sclerosis.
Franz DN
Expert Rev Anticancer Ther; 2011 Aug; 11(8):1181-92. PubMed ID: 21916571
[TBL] [Abstract][Full Text] [Related]
31. Pharmacological treatment strategies for subependymal giant cell astrocytoma (SEGA).
Ebrahimi-Fakhari D; Franz DN
Expert Opin Pharmacother; 2020 Aug; 21(11):1329-1336. PubMed ID: 32338549
[TBL] [Abstract][Full Text] [Related]
32. Mutational analysis of TSC1 and TSC2 genes in Tuberous Sclerosis Complex patients from Greece.
Avgeris S; Fostira F; Vagena A; Ninios Y; Delimitsou A; Vodicka R; Vrtel R; Youroukos S; Stravopodis DJ; Vlassi M; Astrinidis A; Yannoukakos D; Voutsinas GE
Sci Rep; 2017 Dec; 7(1):16697. PubMed ID: 29196670
[TBL] [Abstract][Full Text] [Related]
33. Renal Cell Carcinoma in Tuberous Sclerosis Complex.
Henske EP; Cornejo KM; Wu CL
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680979
[TBL] [Abstract][Full Text] [Related]
34. Sirolimus relieves seizures and neuropsychiatric symptoms via changes of microglial polarity in tuberous sclerosis complex model mice.
Koike-Kumagai M; Fujimoto M; Wataya-Kaneda M
Neuropharmacology; 2022 Nov; 218():109203. PubMed ID: 35931213
[TBL] [Abstract][Full Text] [Related]
35. Recent Advances and Challenges of mTOR Inhibitors Use in the Treatment of Patients with Tuberous Sclerosis Complex.
Palavra F; Robalo C; Reis F
Oxid Med Cell Longev; 2017; 2017():9820181. PubMed ID: 28386314
[TBL] [Abstract][Full Text] [Related]
36. Tuberous Sclerosis: A New Frontier in Targeted Treatment of Autism.
Davis PE; Peters JM; Krueger DA; Sahin M
Neurotherapeutics; 2015 Jul; 12(3):572-83. PubMed ID: 25986747
[TBL] [Abstract][Full Text] [Related]
37. Tuberous sclerosis complex.
Hasbani DM; Crino PB
Handb Clin Neurol; 2018; 148():813-822. PubMed ID: 29478616
[TBL] [Abstract][Full Text] [Related]
38. Safety and efficacy of mTOR inhibitor treatment in patients with tuberous sclerosis complex under 2 years of age - a multicenter retrospective study.
Saffari A; Brösse I; Wiemer-Kruel A; Wilken B; Kreuzaler P; Hahn A; Bernhard MK; van Tilburg CM; Hoffmann GF; Gorenflo M; Hethey S; Kaiser O; Kölker S; Wagner R; Witt O; Merkenschlager A; Möckel A; Roser T; Schlump JU; Serfling A; Spiegler J; Milde T; Ziegler A; Syrbe S
Orphanet J Rare Dis; 2019 May; 14(1):96. PubMed ID: 31053163
[TBL] [Abstract][Full Text] [Related]
39. Everolimus improves neuropsychiatric symptoms in a patient with tuberous sclerosis carrying a novel TSC2 mutation.
Hwang SK; Lee JH; Yang JE; Lim CS; Lee JA; Lee YS; Lee K; Kaang BK
Mol Brain; 2016 May; 9(1):56. PubMed ID: 27216612
[TBL] [Abstract][Full Text] [Related]
40. Tuberous sclerosis complex.
Henske EP; Jóźwiak S; Kingswood JC; Sampson JR; Thiele EA
Nat Rev Dis Primers; 2016 May; 2():16035. PubMed ID: 27226234
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]